Securities Code: 002422 Securities Abbreviation: Kelun Pharmaceutical Announcement No.: 2026-042 Sichuan Kelun Pharmaceutical Co., Ltd. Announcement on the Approval of Subsidiary SKB118 New Drug Clinical Trial Application by the National Medical Products Administration The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false representations, misleading statements, or material omissions. Sichuan Kelun Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") recently learned that its holding subsidiary, Sichuan Kelun Botai Biopharmaceutical Co., Ltd. (hereinafter referred to as "Kelun Botai"), has received a Notice of Clinical Trial from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approving the Investigational New Drug (IND) application for SKB118 (also known as
002422SZSE
🚨 Material Event
Announcement on the Approval of Subsidiary SKB118 New Drug Clinical Trial Application by the National Medical Products Administration
✨ AI Summary
Sichuan Kelun Pharmaceutical Co., Ltd. announces that its subsidiary has received approval from the NMPA for the IND application of SKB118, a PD-1 x VEGF bispecific antibody, for advanced solid tumors. A strategic partnership with Crescent Biopharma grants exclusive rights for Greater China. The FDA has also approved the IND for a global Phase I/II trial in the US.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· gemini_document
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.